Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms

Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have diabetes. Moreover, patients with hypertension often exhibit insulin resistance and are at greater risk of diabetes developing than are normotensive individuals. The major cause of morbidity and mortality in diabetes is cardiovascular disease, which is exacerbated by hypertension. Accordingly, diabetes and hypertension are closely interlinked because of similar risk factors, such as endothelial dysfunction, vascular inflammation, arterial remodelling, atherosclerosis, dyslipidemia, and obesity. There is also substantial overlap in the cardiovascular complications of diabetes and hypertension related primarily to microvascular and macrovascular disease. Common mechanisms, such as upregulation of the renin-angiotensin-aldosterone system, oxidative stress, inflammation, and activation of the immune system likely contribute to the close relationship between diabetes and hypertension. In this article we discuss diabetes and hypertension as comorbidities and discuss the pathophysiological features of vascular complications associated with these conditions. We also highlight some vascular mechanisms that predispose to both conditions, focusing on advanced glycation end products, oxidative stress, inflammation, the immune system, and microRNAs. Finally, we provide some insights into current therapies targeting diabetes and cardiovascular complications and introduce some new agents that may have vasoprotective therapeutic potential in diabetes.

[1]  R. Touyz,et al.  Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.

[2]  M. Vacca,et al.  Integrative miRNA and whole-genome analyses of epicardial adipose tissue in patients with coronary atherosclerosis. , 2016, Cardiovascular research.

[3]  Alexander S. Banks,et al.  SirT1 Regulates Adipose Tissue Inflammation , 2011, Diabetes.

[4]  Benjamin S. Aribisala,et al.  Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes , 2015, Diabetes Care.

[5]  D. Webb,et al.  Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. , 1996, Circulation.

[6]  Y. Hung,et al.  Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes , 2011, Acta Diabetologica.

[7]  R. DeFronzo,et al.  The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. , 1975, The Journal of clinical investigation.

[8]  E. Ferrannini,et al.  β-Cell function in type 2 diabetes. , 2014, Metabolism: clinical and experimental.

[9]  C. Spadaccio,et al.  Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease , 2015, Research in cardiovascular medicine.

[10]  E. Ferrannini,et al.  CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis , 2016, Diabetes Care.

[11]  S. Haffner,et al.  Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites. San Antonio Heart Study. , 1990, American journal of epidemiology.

[12]  A. Mooradian Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm , 2016, Drugs.

[13]  J. Shaw,et al.  IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.

[14]  K. Andrews,et al.  NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis , 2013, Circulation.

[15]  P. Libby,et al.  Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. , 2007, The American journal of cardiology.

[16]  Seppo Lehto,et al.  Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. , 2005, Diabetes care.

[17]  M. Donath Targeting inflammation in the treatment of type 2 diabetes: time to start , 2014, Nature Reviews Drug Discovery.

[18]  Xiaomin Liu,et al.  Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus. , 2008, The American journal of cardiology.

[19]  M. Barton,et al.  Accelerated Vascular Aging as a Paradigm for Hypertensive Vascular Disease: Prevention and Therapy. , 2016, The Canadian journal of cardiology.

[20]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[21]  I. Alexa,et al.  [Oxidative stress in atherosclerosis]. , 2003, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi.

[22]  Ann L. Albright,et al.  Prevalence of diabetic retinopathy in the United States, 2005-2008. , 2010, JAMA.

[23]  S. Haffner,et al.  Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study , 2013, Diabetologia.

[24]  Jiang He,et al.  Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. , 2015, Circulation.

[25]  S. Kaneko,et al.  DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization , 2016, Diabetes.

[26]  F. Cosentino,et al.  Epigenetics and Immunometabolism in Diabetes and Aging , 2017, Antioxidants & redox signaling.

[27]  P. Scherer,et al.  Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis , 2013, Journal of Lipid Research.

[28]  D. Kass,et al.  Mechanisms, pathophysiology, and therapy of arterial stiffness. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[29]  K. Jandeleit-Dahm,et al.  Linking RAGE and Nox in diabetic micro- and macrovascular complications. , 2015, Diabetes & metabolism.

[30]  Andrea De Gaetano,et al.  Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[31]  T. Sano,et al.  [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[32]  Tanya M. Teslovich,et al.  The Metabochip, a Custom Genotyping Array for Genetic Studies of Metabolic, Cardiovascular, and Anthropometric Traits , 2012, PLoS genetics.

[33]  A. Planas,et al.  Sphingosine-1-phosphate signalling—a key player in the pathogenesis of Angiotensin II-induced hypertension , 2017, Cardiovascular research.

[34]  J. Uribarri,et al.  Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both? , 2013, Current Diabetes Reports.

[35]  P Ducimetière,et al.  Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. , 1993, BMJ.

[36]  E. Ferrannini Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. , 2017, Cell metabolism.

[37]  Myung‐Sook Choi,et al.  Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease , 2014, International journal of molecular sciences.

[38]  R. Touyz,et al.  Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[39]  R. Neviere,et al.  Kidney, heart and brain: three organs targeted by ageing and glycation. , 2017, Clinical science.

[40]  R. Brook,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[41]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[42]  M. Volpe,et al.  An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. , 2017, Cardiovascular research.

[43]  D. Kass,et al.  Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker , 2001, Circulation.

[44]  R. Touyz,et al.  Drug Treatment of Hypertension: Focus on Vascular Health , 2016, Drugs.

[45]  Xinghui Sun,et al.  Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy. , 2017, Endocrine reviews.

[46]  R. de Caterina,et al.  Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches. , 2017, Vascular pharmacology.

[47]  N. Billestrup,et al.  Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus , 2011, Molecular medicine.

[48]  M. Woodward,et al.  Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes , 2017, Cardiovascular Diabetology.

[49]  R. Ramasamy,et al.  Unlocking the biology of RAGE in diabetic microvascular complications , 2014, Trends in Endocrinology & Metabolism.

[50]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[51]  M. Volpe,et al.  Vascular Inflammation and Endothelial Dysfunction in Experimental Hypertension , 2011, International journal of hypertension.

[52]  O. Pedersen,et al.  Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial , 2016, Diabetologia.

[53]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[54]  Saum A. Rahimi,et al.  Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques. , 2016, Cardiovascular research.

[55]  N. Agrawal,et al.  Targeting inflammation in diabetes: Newer therapeutic options. , 2014, World journal of diabetes.

[56]  S. Quaggin,et al.  Therapies on the Horizon for Diabetic Kidney Disease , 2015, Current Diabetes Reports.

[57]  A. Schmidt 22016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis and Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage. , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[58]  R. McPherson,et al.  Partitioning the heritability of coronary artery disease highlights the importance of immune-mediated processes and epigenetic sites associated with transcriptional activity , 2017, Cardiovascular research.

[59]  Michael E. Miller,et al.  Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial , 2014, Diabetes Care.

[60]  M. Anselmino,et al.  Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery , 2017, Scientific Reports.

[61]  K. Channon,et al.  Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase , 2002, Circulation.

[62]  M. Saad,et al.  Insulin resistance in essential hypertension. , 1990, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[63]  P. Libby,et al.  Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists , 2007 .

[64]  Hong Nie,et al.  Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[65]  R. Taylor,et al.  Restoring normoglycaemia by use of a very low calorie diet in long‐ and short‐duration Type 2 diabetes , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[66]  Liam G. Fearnley,et al.  An interaction map of circulating metabolites, immune gene networks, and their genetic regulation , 2016, Genome Biology.

[67]  K. Otsu,et al.  Inflammation and metabolic cardiomyopathy. , 2017, Cardiovascular research.

[68]  A. Schmidt 22016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis and Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage. , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[69]  D. Hardie,et al.  The mechanisms of action of metformin , 2017, Diabetologia.

[70]  Rong Li,et al.  Metformin improves obesity-associated inflammation by altering macrophages polarization , 2017, Molecular and Cellular Endocrinology.

[71]  Nathan Congdon,et al.  The Prevalence of Diabetic Retinopathy in the United States , 2002 .

[72]  G. Hotamışlıgil Inflammation, metaflammation and immunometabolic disorders , 2017, Nature.

[73]  L. Moran,et al.  Treatment with high dose salicylates improves cardiometabolic parameters: Meta-analysis of randomized controlled trials. , 2017, Metabolism: clinical and experimental.

[74]  M. Banerjee,et al.  Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[75]  K. Ward,et al.  The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction , 2017, Cardiovascular Diabetology.

[76]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[77]  H. Parving,et al.  Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial , 2008, The Lancet.

[78]  R. Touyz,et al.  Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. , 2014, Journal of the American Society of Nephrology : JASN.

[79]  R. DeFronzo,et al.  Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. , 2015, European heart journal.

[80]  P. Formisano,et al.  Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage , 2017, International journal of molecular sciences.

[81]  J. Petrie The cardiovascular safety of incretin-based therapies: a review of the evidence , 2013, Cardiovascular Diabetology.

[82]  Krishna A. Adeshara,et al.  Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies. , 2016, Current drug targets.

[83]  J. Loscalzo,et al.  Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia , 2002, Vascular medicine.

[84]  Lawrence A Leiter,et al.  Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. , 2017, The Canadian journal of cardiology.

[85]  J. Pickering,et al.  Cellular Senescence and Vascular Disease: Novel Routes to Better Understanding and Therapy. , 2016, The Canadian journal of cardiology.

[86]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[87]  G. Freund,et al.  The implication of proinflammatory cytokines in type 2 diabetes. , 2008, Frontiers in bioscience : a journal and virtual library.

[88]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.

[89]  R. Singh,et al.  Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes. , 2011, Diabetes research and clinical practice.

[90]  H R Taylor,et al.  Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[91]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[92]  D. Harrison,et al.  The role of infiltrating immune cells in dysfunctional adipose tissue , 2017, Cardiovascular research.

[93]  W. Malaisse B-cell function in type 2 diabetes , 1990 .

[94]  P. Newsholme,et al.  Molecular mechanisms of ROS production and oxidative stress in diabetes. , 2016, The Biochemical journal.

[95]  R. Touyz,et al.  Oxidative Stress, Inflammation, and Vascular Aging in Hypertension , 2017, Hypertension.

[96]  E. Barrett,et al.  Insulin‐Induced Microvascular Recruitment in Skin and Muscle are Related and Both are Associated with Whole‐Body Glucose Uptake , 2012, Microcirculation.

[97]  L. Chatenoud,et al.  Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice , 2018, Diabetologia.

[98]  A. Scuteri,et al.  Endothelial function and arterial stiffness in normotensive normoglycemic first-degree relatives of diabetic patients are independent of the metabolic syndrome. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[99]  T. Hansen,et al.  Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub‐analysis of a randomized, placebo‐controlled, double‐blind, crossover trial , 2017, Diabetes, obesity & metabolism.

[100]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[101]  P. Pozzilli,et al.  Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes? , 2013, Diabetes Care.

[102]  Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis an Treatment of Cardiometabolic Disorders : Spotlight on the Macrophage , 2017 .

[103]  R. Touyz,et al.  Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. , 2013, Clinical science.

[104]  C. Antoniades 'Dysfunctional' adipose tissue in cardiovascular disease: a reprogrammable target or an innocent bystander? , 2017, Cardiovascular research.

[105]  D. Drucker The Cardiovascular Biology of Glucagon-like Peptide-1. , 2016, Cell metabolism.

[106]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[107]  B. Wells,et al.  Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system , 2015, BMJ Open Diabetes Research and Care.

[108]  H. Grallert,et al.  Effects of Genetic Loci Associated with Central Obesity on Adipocyte Lipolysis , 2016, PloS one.

[109]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. , 1998, Nature.

[110]  D. Power,et al.  NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy , 2017, Diabetes.

[111]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[112]  N. Mishra,et al.  Role of MicroRNAs in Type 2 Diabetes and Associated Vascular Complications. , 2017, Biochimie.

[113]  K. Lackner,et al.  The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats , 2017, Redox biology.

[114]  J. Whitehead,et al.  Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress , 2014, Nature Medicine.

[115]  R. Touyz,et al.  Vascular biology of ageing—Implications in hypertension , 2015, Journal of Molecular and Cellular Cardiology.

[116]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[117]  F. Rubino,et al.  Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial , 2015, The Lancet.

[118]  A. Donker,et al.  Effects of short‐term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo‐controlled trial , 2005, Journal of internal medicine.

[119]  E. Schiffrin,et al.  Oxidative Stress, Nox Isoforms and Complications of Diabetes—Potential Targets for Novel Therapies , 2012, Journal of Cardiovascular Translational Research.

[120]  C. Peterson,et al.  Pioglitazone Treatment Reduces Adipose Tissue Inflammation through Reduction of Mast Cell and Macrophage Number and by Improving Vascularity , 2014, PloS one.

[121]  A. Ferro,et al.  The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials. , 2016, Cardiovascular research.

[122]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.

[123]  A. Donker,et al.  Long‐term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial , 2014, Journal of internal medicine.

[124]  P. Wilson,et al.  The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. , 1988, JAMA.